Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.14 USD | +1.56% | -6.63% | +19.14% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 494M |
---|---|---|---|---|---|
Net income 2024 * | -79M | Net income 2025 * | -101M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-5.81
x | P/E ratio 2025 * |
-4.57
x | Employees | 59 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.7% |
Latest transcript on Astria Therapeutics, Inc.
1 day | +1.61% | ||
1 week | -6.63% | ||
Current month | -34.99% | ||
1 month | -32.27% | ||
3 months | -24.32% | ||
6 months | +92.23% | ||
Current year | +19.14% |
Managers | Title | Age | Since |
---|---|---|---|
Jill Milne
FOU | Founder | 56 | 08-06-25 |
Noah Clauser
DFI | Director of Finance/CFO | 51 | 11-03-31 |
Chief Tech/Sci/R&D Officer | - | 22-07-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ken Bate
CHM | Chairman | 73 | 13-12-31 |
Gregg Lapointe
BRD | Director/Board Member | 65 | 19-01-03 |
Director/Board Member | 75 | 16-04-04 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 2 M€ | -.--% | ||
0.00% | 34 M€ | +2.43% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 9.145 | +1.61% | 448 057 |
24-04-26 | 9 | -1.85% | 1,133,619 |
24-04-25 | 9.17 | +1.89% | 1,324,385 |
24-04-24 | 9 | -6.64% | 659,022 |
24-04-23 | 9.64 | -1.63% | 748,168 |
Delayed Quote Nasdaq, April 29, 2024 at 03:31 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.14% | 494M | |
-2.86% | 103B | |
+1.42% | 95.28B | |
+1.46% | 22.15B | |
-16.10% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.16% | 16.05B | |
+5.38% | 13.68B | |
+33.44% | 12.17B |
- Stock Market
- Equities
- ATXS Stock